Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article examines the PCPT study on whether daily finasteride can reduce prostate cancer incidence, describing its methodology and findings but reporting no new clinical results.

This study found that both finasteride and dutasteride reduced the risk of prostate cancer detection, but finasteride was associated with an increased diagnosis of higher-grade disease, unlike dutasteride.

This study found that six weeks of finasteride therapy before TURP reduced intraoperative blood loss and improved early postoperative quality of life in patients with benign prostatic hyperplasia.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This study concluded that male patients with improved lower urinary tract symptoms may have a lower risk of death, suggesting a potential benefit of treating symptoms beyond just managing patient discomfort.

New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

This study found that men who began balding at age 20 were twice as likely to develop prostate cancer later in life compared to those who did not experience early hair loss.

This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.

This study found that the epithelial changes in benign prostatic hyperplasia treated with finasteride resembled the pattern of healthy prostates.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study reports that prostate volume, operation time, resected tissue weight, and smoking increase risks of blood loss and fluid absorption during PK-TURP, while finasteride treatment and surgeon experience may reduce these risks.

Large prostate patients more likely to have hair loss.

This article discusses the potential of using flutamide and finasteride for complete androgen blockade in early-stage, low-grade prostate cancer and suggests they may improve symptom-free and overall survival compared to observation.

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This review discusses chemoprevention for prostate cancer and suggests that further open and unbiased investigation into various preventive compounds, including 5α-reductase inhibitors, is needed.

Finasteride significantly reduces the risk of prostate cancer.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

This study found that combining longxuejie and finasteride effectively reduced intra-operative bleeding during TURP without side effects compared to finasteride, longxuejie alone, or control.

5-ARI therapy may help prevent prostate cancer progression.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

Finasteride treats hair loss but may affect prostate cancer detection.

This study found that terazosin, finasteride, or their combination were effective in treating symptoms of benign prostatic hyperplasia.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This study found that one year of finasteride treatment significantly reduced PSA levels and prostate volume in men with elevated PSA and negative prior biopsy, potentially aiding prostate cancer diagnosis.